2598:基于电化学血清的神经胶质瘤早期诊断和分层平台

Christopher Rinaldi, A. G. Theakstone, D. Corrigan, Paul Brennan, M. Baker
{"title":"2598:基于电化学血清的神经胶质瘤早期诊断和分层平台","authors":"Christopher Rinaldi, A. G. Theakstone, D. Corrigan, Paul Brennan, M. Baker","doi":"10.1158/1538-7445.AM2021-2598","DOIUrl":null,"url":null,"abstract":"Development of an electrochemical diagnostic test would provide quantitative detection of biomarkers characteristic of clinical serum samples that may facilitate early detection and triage of glioma patients in the clinical setting. Today, 32 individuals will receive a confirmatory diagnosis of a brain tumor in the UK, equivalent to 3% of all patients diagnosed with cancer annually. Implications for patients and families are tragic, brain cancer is responsible for >5,000 mortalities annually in the UK, with 20.1 mean years of life lost to the disease per patient, greater than any other cancer. Presently, ~22% of brain cancer patients receive diagnosis through GP referral, with over a third of patients attending their health practice on five occasions prior to diagnosis. Brain tumor symptoms are diverse and often non-specific in the absence of epileptic seizures, with an extremely poor positive predictive value. Consequently, suspected patients experience significant diagnostic delays, with significant time spent in primary care settings. Heightened symptoms often translates to emergency presentation, where >60% of brain cancer patients currently receive diagnosis, associated with reduced survival compared to non-emergency pathways. Hence, earlier detection of brain cancer patients is a clinical need within primary care settings to prevent significant diagnostic delays and improve patient outcomes. Introduction of a widespread screening program with medical imaging modalities is not economically viable for early detection of brain cancer given high test costs and low incidence in the general population. However, a recent health economic study suggested a blood-based test may prove cost saving to NHS services if employed to triage brain tumor patients for medical imaging in primary and secondary care. Blood is fundamental to physiological function of cells and their perpetual interaction provides a rich source of endogenous molecules that may reflect biochemical events of gliomagenesis. Our current work towards development of a blood-based electrochemical platform for brain cancer focuses on screening of clinical serum samples for a large panel of cytokines from confirmed patients with glioma tumor types. Thereafter, our work demonstrates electrochemical detection of elevated cytokine biomarkers identified within our serum samples. Previously, we demonstrated the potential of this platform technology for early detection of Hodgkin lymphoma, with successful discrimination between cancerous and non-cancerous patient samples, which we now hope to extend to early detection of brain cancer. Implementation of a low-cost, point-of-care triage blood test for brain cancer would have significant clinical and economical benefits, ultimately facilitating the promotion of early detection strategies in primary care to enable timely cancer diagnosis and improve patient outcomes. Citation Format: Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker. Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2598.","PeriodicalId":20290,"journal":{"name":"Prevention Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract 2598: Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma\",\"authors\":\"Christopher Rinaldi, A. G. Theakstone, D. Corrigan, Paul Brennan, M. Baker\",\"doi\":\"10.1158/1538-7445.AM2021-2598\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Development of an electrochemical diagnostic test would provide quantitative detection of biomarkers characteristic of clinical serum samples that may facilitate early detection and triage of glioma patients in the clinical setting. Today, 32 individuals will receive a confirmatory diagnosis of a brain tumor in the UK, equivalent to 3% of all patients diagnosed with cancer annually. Implications for patients and families are tragic, brain cancer is responsible for >5,000 mortalities annually in the UK, with 20.1 mean years of life lost to the disease per patient, greater than any other cancer. Presently, ~22% of brain cancer patients receive diagnosis through GP referral, with over a third of patients attending their health practice on five occasions prior to diagnosis. Brain tumor symptoms are diverse and often non-specific in the absence of epileptic seizures, with an extremely poor positive predictive value. Consequently, suspected patients experience significant diagnostic delays, with significant time spent in primary care settings. Heightened symptoms often translates to emergency presentation, where >60% of brain cancer patients currently receive diagnosis, associated with reduced survival compared to non-emergency pathways. Hence, earlier detection of brain cancer patients is a clinical need within primary care settings to prevent significant diagnostic delays and improve patient outcomes. Introduction of a widespread screening program with medical imaging modalities is not economically viable for early detection of brain cancer given high test costs and low incidence in the general population. However, a recent health economic study suggested a blood-based test may prove cost saving to NHS services if employed to triage brain tumor patients for medical imaging in primary and secondary care. Blood is fundamental to physiological function of cells and their perpetual interaction provides a rich source of endogenous molecules that may reflect biochemical events of gliomagenesis. Our current work towards development of a blood-based electrochemical platform for brain cancer focuses on screening of clinical serum samples for a large panel of cytokines from confirmed patients with glioma tumor types. Thereafter, our work demonstrates electrochemical detection of elevated cytokine biomarkers identified within our serum samples. Previously, we demonstrated the potential of this platform technology for early detection of Hodgkin lymphoma, with successful discrimination between cancerous and non-cancerous patient samples, which we now hope to extend to early detection of brain cancer. Implementation of a low-cost, point-of-care triage blood test for brain cancer would have significant clinical and economical benefits, ultimately facilitating the promotion of early detection strategies in primary care to enable timely cancer diagnosis and improve patient outcomes. Citation Format: Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker. Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2598.\",\"PeriodicalId\":20290,\"journal\":{\"name\":\"Prevention Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prevention Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.AM2021-2598\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prevention Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.AM2021-2598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

电化学诊断测试的发展将为临床血清样本的生物标志物特征提供定量检测,这可能有助于在临床环境中对胶质瘤患者进行早期检测和分类。今天,英国将有32人接受脑肿瘤确诊,相当于每年所有癌症确诊患者的3%。脑癌对患者和家属的影响是悲惨的,在英国,脑癌每年导致5000多人死亡,每个患者平均寿命减少20.1年,比任何其他癌症都要多。目前,约22%的脑癌患者通过全科医生转诊得到诊断,超过三分之一的患者在诊断前曾到他们的诊所就诊五次。脑肿瘤的症状多种多样,在没有癫痫发作的情况下往往是非特异性的,阳性预测值极低。因此,疑似患者经历了严重的诊断延误,在初级保健机构花费了大量时间。症状加重往往转化为紧急情况,目前超过60%的脑癌患者接受诊断,与非紧急途径相比,生存率降低。因此,早期发现脑癌患者是初级保健机构的临床需要,以防止严重的诊断延误并改善患者的预后。由于检测费用高,普通人群发病率低,采用医学成像方式进行广泛筛查在经济上并不可行。然而,最近的一项卫生经济学研究表明,如果采用血液检测对脑肿瘤患者进行初级和二级医疗成像分类,可能会为NHS服务节省成本。血液是细胞生理功能的基础,它们之间的持续相互作用提供了丰富的内源性分子来源,这些内源性分子可能反映胶质瘤发生的生化事件。我们目前的工作是开发一种基于血液的脑癌电化学平台,重点是筛选来自胶质瘤肿瘤类型确诊患者的大量细胞因子的临床血清样本。此后,我们的工作证明了电化学检测在我们的血清样本中鉴定的升高的细胞因子生物标志物。此前,我们展示了该平台技术在早期检测霍奇金淋巴瘤方面的潜力,成功区分了癌变和非癌变患者样本,我们现在希望将其扩展到早期检测脑癌。实施一种低成本、即时分诊的脑癌血液检测将具有显著的临床和经济效益,最终有助于在初级保健中推广早期发现策略,从而能够及时诊断癌症并改善患者的预后。引用格式:Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker。基于电化学血清的神经胶质瘤早期诊断和分层平台[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志,2021;81(13 -增刊):摘要第2598期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Abstract 2598: Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma
Development of an electrochemical diagnostic test would provide quantitative detection of biomarkers characteristic of clinical serum samples that may facilitate early detection and triage of glioma patients in the clinical setting. Today, 32 individuals will receive a confirmatory diagnosis of a brain tumor in the UK, equivalent to 3% of all patients diagnosed with cancer annually. Implications for patients and families are tragic, brain cancer is responsible for >5,000 mortalities annually in the UK, with 20.1 mean years of life lost to the disease per patient, greater than any other cancer. Presently, ~22% of brain cancer patients receive diagnosis through GP referral, with over a third of patients attending their health practice on five occasions prior to diagnosis. Brain tumor symptoms are diverse and often non-specific in the absence of epileptic seizures, with an extremely poor positive predictive value. Consequently, suspected patients experience significant diagnostic delays, with significant time spent in primary care settings. Heightened symptoms often translates to emergency presentation, where >60% of brain cancer patients currently receive diagnosis, associated with reduced survival compared to non-emergency pathways. Hence, earlier detection of brain cancer patients is a clinical need within primary care settings to prevent significant diagnostic delays and improve patient outcomes. Introduction of a widespread screening program with medical imaging modalities is not economically viable for early detection of brain cancer given high test costs and low incidence in the general population. However, a recent health economic study suggested a blood-based test may prove cost saving to NHS services if employed to triage brain tumor patients for medical imaging in primary and secondary care. Blood is fundamental to physiological function of cells and their perpetual interaction provides a rich source of endogenous molecules that may reflect biochemical events of gliomagenesis. Our current work towards development of a blood-based electrochemical platform for brain cancer focuses on screening of clinical serum samples for a large panel of cytokines from confirmed patients with glioma tumor types. Thereafter, our work demonstrates electrochemical detection of elevated cytokine biomarkers identified within our serum samples. Previously, we demonstrated the potential of this platform technology for early detection of Hodgkin lymphoma, with successful discrimination between cancerous and non-cancerous patient samples, which we now hope to extend to early detection of brain cancer. Implementation of a low-cost, point-of-care triage blood test for brain cancer would have significant clinical and economical benefits, ultimately facilitating the promotion of early detection strategies in primary care to enable timely cancer diagnosis and improve patient outcomes. Citation Format: Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker. Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2598.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信